-
Lifevantage (LFVN) Declares $0.045 Quarterly Dividend; 2.6% Yield
-
LifeVantage completes LoveBiome acquisition for microbiome expansion
-
Lifevantage (LFVN) Tops Q4 EPS by 1c; offers guidance
-
LifeVantage to acquire microbiome health company LoveBiome
-
Lifevantage (LFVN) Declares $0.045 Quarterly Dividend; 1.4% Yield
-
LifeVantage reports clinical study shows 200% increase in GLP-1 production
-
Lifevantage (LFVN) Tops Q3 EPS by 6c
-
Lifevantage (LFVN) Raises Quarterly Dividend 12.5% to $0.045; 1.5% Yield
-
Lifevantage (LFVN) Launches LV360 and Evolve Compensation Plan in Philippines, Taiwan, Hong Kong, and Singapore Markets
-
Lifevantage (LFVN) Tops Q2 EPS by 8c, offers guidance
-
Lifevantage (LFVN) Announces Completion of International In Vitro Study on the MB System
-
Lifevantage (LFVN) Appoints Todd Thompson as Chief Information and Innovation Officer
-
Craig-Hallum Starts Lifevantage Corporation (LFVN) at Buy
-
Lifevantage (LFVN) Study Confirms Breakthrough Synergistic Effects of Healthy Weight Stack
-
Lifevantage (LFVN) Launches 2025 Vision with “Drive ERA” Theme and International Expansion Plans for Evolve Compensation Plan and the MindBody GLP-1 System
-
Lifevantage (LFVN) Misses Q1 EPS by 2c, provides guidance
-
Lifevantage (LFVN) Declares $0.04 Quarterly Dividend; 1.3% Yield
-
Lifevantage (LFVN) Completes Successful Human Clinical Trial with New GLP-1 System for Activated Weight Loss
-
Lifevantage (LFVN) Announces Positive In Vitro Results for New GLP-1 System
-
Lifevantage (LFVN) Misses Q4 EPS by 7c, provides guidance
-
Lifevantage (LFVN) Declares $0.04 Quarterly Dividend; 1.8% Yield

